You are here: Industry Insights > Sanofi

News List

Sanofi provides update on Kevzara? (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. worldpharmanews
September 02, 2020
Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara? (sarilumab) at a dose of 200 mg or 400 mg[1] in severely or critically ill[2] patients hospitalized with COVID-19 did not meet its primary endpoint and ...
Kevzara fails in PhIII COVID-19 trial pharmatimes
September 02, 2020
Sanofi and Regeneron's rheumatoid arthritis drug Kevzara (sarilumab) has failed to hit targets in a late-stage trial involving patients hospitalised with COVID-19, signalling the end of its development in this area.
Sanofi backs mental health mission of 'Let's Talk' documentary focused on blood disease patients fiercepharma
September 01, 2020
One young man relives the day he stood at the edge of a cliff and considered suicide—that's the opening scene in a new Sanofi-sponsored documentary that tackles mental health issues among people with blood disorders.
Sanofi to acquire Principa Biopharma for $3.68 billion europeanpharmaceuticalreview
August 21, 2020
Sanofi is set to acquire Principia Biopharma Inc. for a total aggregate equity value of $3.68 billion, at $100 per share.
Sanofi to acquire Principia Biopharma expresspharma
August 18, 2020
The deal adds to Sanofi’s R&D areas of autoimmune and allergic diseases.
Manslaughter charges on Sanofi over epilepsy drug Depakine expresspharma
August 05, 2020
Sanofi Aventis France has been placed under formal investigation on charges of manslaughter over Depakine, an epilepsy drug that caused birth malfunctions and slow neurological development when taken during pregnancy.
Sanofi and GSK Selected for Operation Warp Speed contractpharma
August 04, 2020
To supply U.S. government with 100 million doses of COVID-19 vaccine in $2.1 billion deal.
US commits $2.1bn for 100 million Sanofi-GSK Covid-19 vaccine doses pharmaceutical-technology
August 03, 2020
The US Government has committed to providing up to $2.1bn to Sanofi and GlaxoSmithKline (GSK) for development, manufacturing, scale-up and delivery of an initial 100 million doses of the companies’ Covid-19 vaccine candidate.
Sanofi, GSK to supply 100 mn doses of COVID-19 vaccine to US, in talks with EU for 300 mn doses expresspharma
August 03, 2020
The deal is worth $2.1 billion and involves the supply of vaccines for 50 million people, with the option to buy another 500 million doses.
UK strikes deal with GSK and Sanofi for 60 mn doses of COVID-19 vaccine expresspharma
July 30, 2020
The British government said the latest deal helps grow the country’s portfolio of vaccine candidates and adds to previous agreements.